Database Analysis of Eplerenone Use in Japanese Hypertensive Patients in Clinical Practice

Table 2

Concomitant antihypertensives received for concomitant diseases: patients on all antihypertensive drugs during the last claim month of stable treatment (≥ six months of treatment with the same drugs).

	Total N	Cardiovascular disease	Diabetes	Heart failure	Renal disease
		N (%)	N (%)	N (%)	N (%)
All	160,996	52,863 (32.8)	56,220 (34.9)	13,589 (8.4)	11,677 (7.3)
Beta blocker	23,087	12,429 (53.8)	9,164 (39.7)	5,648 (24.5)	1,900 (8.2)
Diuretics	19,565	7,380 (37.7)	7,879 (40.3)	2,988 (15.3)	1,938 (9.9)
Eplerenone	1,208	580 (48.0)	557 (46.1)	336 (27.8)	136 (11.3)
Spironolactone	2,078	1,241 (59.7)	1,112 (53.5)	997 (48.0)	248 (11.9)
ACE inhibitor	11,057	4,898 (44.3)	4,824 (43.6)	1,893 (17.1)	1,167 (10.6)
Alpha blocker	5,735	2,246 (39.2)	2,290 (39.9)	580 (10.1)	779 (13.6)
CCB	109,166	34,733 (31.8)	37,364 (34.2)	7,552 (6.9)	7,247 (6.6)
ARB	101,557	33,256 (32.7)	38,010 (37.4)	8,294 (8.2)	8,419 (8.3)
Others	1,014	438 (43.2)	453 (44.7)	166 (16.4)	265 (26.1)

ACE inhibitor: angiotensin-converting-enzyme inhibitor, CCB: calcium channel blocker, and ARB: angiotensin II receptor blocker.
Note: four patients who were prescribed both eplerenone and spironolactone have been counted twice.